- Agreement provides Alexion with exclusive worldwide licenses for one preclinical target, with option for up to three additional targets, in the complement pathway - BOSTON & COPENHAGEN, ...

Alexion Pharmaceuticals will apply Dicerna Pharmaceuticals’ GalXC™ platform to discover and develop RNA interference (RNAi) therapies for complement-mediated diseases, through a collaboration that ...

In this paper, we obtain the eigenvalues and Laplacian eigenvalues of the unitary addition Cayley graph Gn and its complement. Moreover, we compute the bounds for energy and Laplacian energy for Gn ...